ResMed study shows benefits of APV therapy for sleep apnoea

Medical Company Product News

ResMed has announced new data from a clinical study demonstrating the advantages of providing sleep apnoea patients with the option of adaptive servo-ventilation (ASV) therapy.

Findings from the largest-ever analysis of patients with treatment-emergent central sleep apnoea indicated that patients are more compliant on therapy after switching from continuous positive airway pressure (CPAP) therapy to ASV treatment.

“ResMed has reported the findings of a new study showing the benefits of adaptive servo-ventilation therapy for the treatment of sleep apnoea.“

Data from the devices of 198,890 telemonitored US patients who were receiving positive airway pressure therapy was analysed, showing a 62.7 percent compliance rate among patients on CPAP, compared to 76.6 percent after switching to ASV.

This meant those who switched from CPAP to ASV used their therapy longer and had significantly fewer apnoeas during sleep.

According to ResMed, this study highlights the need to consider therapeutic options for sleep apnoea based on each patient's disease severity.

Dr Carlos Nunez, ResMed's chief medical officer, said: "These findings underscore the importance of continuously monitoring central sleep apnoea and rethinking the conventional wisdom on therapeutic options based on each patient's disease severity."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news

Tags